FindTrial
Sign In

How genetic changes affect the occurrence and outlook of endometrial cancer

Incidence and prognostic impact of genomic alteration in endometrial cancer - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/03/083162
Enrollment
30
Registered
2025-03-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C55- Malignant neoplasm of uterus, partunspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Inimerla Bhavya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All cases of endometrial carcinoma attending medical oncology and surgical oncology OPD irrespective of stage.

Exclusion criteria

Exclusion criteria: Patients who refuse to take part in this study. Patients with other confounding factors such as prior radiation to pelvis, concomitant malignancy, HCV/HBsAg/HIV reactive, active TB, previously treated different malignancy.

Design outcomes

Primary

MeasureTime frame
To determine the incidence of various genomic mutations ( POLE, MSI and TP53 status )in EC by genetic analysis.Timepoint: 3 monthly and 6 monthly—

Secondary

MeasureTime frame
To analyze the clinical outcomes and correlate them with various mutations according to histological variants of EC. To analyze the outcome of POLE mutation, MSI, and TP53 in patients of EC. Timepoint: 3 monthly and 6 monthly—

Countries

India

Contacts

Public ContactDr Inimerla Bhavya

Institute of Medical sciences and SUM Hospital

drgbiswas@gmail.com9937500878

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026